Cholinergic deficiency involved in vascular dementia: Possible mechanism and strategy of treatment

103Citations
Citations of this article
111Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Vascular dementia (VaD) is a progressive neurodegenerative disease with a high prevalence. Several studies have recently reported that VaD patients present cholinergic deficits in the brain and cerebrospinal fluid (CSF) that may be closely related to the pathophysiology of cognitive impairment. Moreover, cholinergic therapies have shown promising effects on cognitive improvement in VaD patients. The precise mechanisms of these cholinergic agents are currently not fully understood; however, accumulating evidence indicates that these drugs may act through the cholinergic anti-inflammatory pathway, in which the efferent vagus nerve signals suppress pro-inflammatory cytokine release and inhibit inflammation, although regulation of oxidative stress and energy metabolism, alleviation of apoptosis may also be involved. In this paper, we provide a brief overview of the cholinergic treatment strategy for VaD and its relevant mechanisms of anti-inflammation. © 2009 CPS and SIMM All rights reserved.

Cite

CITATION STYLE

APA

Wang, J., Zhang, H. Y., & Tang, X. C. (2009, July). Cholinergic deficiency involved in vascular dementia: Possible mechanism and strategy of treatment. Acta Pharmacologica Sinica. https://doi.org/10.1038/aps.2009.82

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free